Implantica publishes Interim Report January – March 2023 (Q1)

RefluxStop™ - Designed for a Revolution in the Care of Acid Reflux

Significant events in the first quarter of 2023

• RefluxStop™ is currently being launched in Scandinavia, with Ersta Hospital and Sundsvall Sjukhus in Sweden, the first centers committing to join our registry study.
• Validated clinical data collection continues for RefluxStop™ with AKH Vienna presenting their results on their first RefluxStop™ patients at the Finnish Gastro Days Congress in Helsinki.
• The first RefluxStop™ surgeries have been performed in Spain as we continue to prepare for the public tender process.
• Another major German Reflux Center, Klinikum Aschaffenburg, completed first RefluxStop cases and also signed up for the Registry study.
• The American Foregut Society (AFS) published a white paper outlining the steps of how acid reflux develops, which further reflects the core RefluxStop™ treatment principles.
• Ethics Committee approval of the registry study has been achieved in Switzerland with Inselspital Bern and Hirslanden Klinik Beau-Site joining the study.
• Successfully completed ISO 13485 and MDSAP recertifications.

Significant events after the end of the period

• The first RefluxStop procedures were performed in Italy at two centers: Ospedale Buon Consiglio Fatebenefratelli in Napoli by Prof. Renzi and IRCCS Ospedale Galeazzi - Sant'Ambrogio in Milan by Prof. Bona, joined by Prof. Bonavina, president of the European Foregut Society.
• The 100th RefluxStop procedure was completed in a single center at Klinikum Friedrichshafen, a leading anti-reflux Center of Excellence in Germany.
• Followed by approval in Switzerland, RefluxStop Registry Study (ReStore) has now also been approved in Germany.
• Dr. med. Borbély from InselSpital, Switzerland’s largest University hospital, presented his successful RefluxStop 3-year results at SAGES (Society of American Gastrointestinal and Endoscopic Surgeons) conference in Montreal, Canada. He concluded that the excellent data from the CE mark study could be replicated in a real-world setting.
• The RefluxStop cost-effectiveness analysis comparing RefluxStop™ against PPIs, Fundoplication and Magnetic Sphincter Augmentation results are now published in the peer-reviewed Journal of Medical Economics well known for covering economic assessments of novel therapeutic and medical device interventions.
• Implantica has been selected as one of 50 Admired Companies to Watch 2023 by CIO Bulletin.

Financial summary first quarter 2023

• Net sales increased 55% to TEUR 307 (198).
• Adjusted gross margin amounted to 95% (95%).
• Operating loss (EBIT) increased to TEUR 4,870 (4,411).
• Loss after tax amounted to TEUR 4,758 (4,888).
• Basic and diluted loss per Class A share amounted to EUR 0.07 (0.07).
• Cash as at the end of the period amounted to MEUR 102.3.

Implantica will hold a telephone conference on May 12 at 15:00 CEST.

Implantica will hold a teleconference with Peter Forsell (CEO), Andreas Öhrnberg (CFO) and Nicole Pehrsson (Chief Corporate Affairs Officer & Investor Relations). Please see dial-in details below to join the conference:
Webcast

https://ir.financialhearings.com/implantica-q1-2023

Dial-in number (toll free)

• SE: +46 850 516 386
• UK: +44 203 198 4884
• US: +1 412 317 6300

(Pin code: 9354290#)

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on May 12, 2023 at 08:00 a.m. (CEST).

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.